PREVIEW | CONFIDENTIAL | BY INVITATION ONLY
BREAKING SCIENCE INTO SPORTS
The Global Fund Exclusively Focused On Sports Science
We FOCUS ON THE SCIENCE OF HUMAN PERFORMANCE
For existing sports investors this is an adjacent bet; we do it exclusively.
The annual market size in global sports is ~$3T USD. The global investment spend in sports is more than $280B USD. The vast majority of that capital goes to teams, leagues, stadiums, and media — less than 3% goes toward the science of optimization, recovery, and performance longevity = human healthspan.
Angela Ruggiero and Sans Thakur, backed by TOWER Capital Group, are changing that.
We bring scientific rigor to the biology of competitiveness, and beyond with a generational lens. In partnership with athletes, whose lived experience helps shape our investment strategy, with the opportunity to be owners.
The generational sports science fund closes the gap.
SCIENCE & SPORT INVESTING: VELOCITY
A Thesis of Differentiated Returns through Athlete & Scientific Strategy
Trillions flow into sport annually; almost none funds the science that drives human performance. Between $80-120 billion USD, in 2025, was invested annually by top private allocators in the US into the sports ecosystem, but only 3% funds the science that drives human performance.
Yet, life sciences has consistently outperformed traditional sports investing. Directing capital into life-sciences-grade assets within the sports category captures that premium while benefiting from the sport's market growth trajectory.
Our arbitrage opportunity: a return profile the market has not yet priced, absent a vehicle and proven expertise built to capture it. Execution is grounded in existing infrastructure within our team: 1,000+ vetted innovations, $28B+ in networked assets, 175+ years of combined experience, and 40+ medicines launched to date — paired with unmatched athlete access and trust.
Expected outcome: life-sciences-grade IRR at sports-sector speed.
Life sciences beats sports investing — on cash, not just paper. Historically, life sciences funds return 1.14x DPI to LPs vs. 1.02x for the broader VC market, and 11.5% of biopharma deals hit a >5x return. Our own analogs show 5.1x–6.8x across verticals.
Pair that return profile with the growth and innovation cycle of sport, and you get the fund's premium.
Collisions of longevity biotechnology : QUANTIFIED ATHLETE | QUANTIFIED SELF
BREAKING SCIENCE INTO SPORT
We invest in technology and human-performance companies that can be stress-tested by the most discerning customers — elite athletes — and scaled to benefit generational health for the rest of the population.
The combined addressable market sitting at the intersection of sports with cutting edge science: digital health and AI ($900B–$1.2T), brain and family health ($880B), AI compute infrastructure ($300B–$600B), genomics ($55B–$60B), and longevity science ($30B–$50B) — and it's all layered on top of a population in need: 1.7 billion people worldwide living with musculoskeletal conditions.
POWERED BY TOWER
1,000+ vetted innovations already in the dealbook
$28B+ in networked TOWER's Generational Health dealbook
Operating leadership across 5 continents
175+ years of combined experience
40+ sciences launched to date
The STRUCTURE
PREMIUM OUTCOMES & PROJECTIONS
The co-founding of elite athlete with successful science of our portfolio analogs with a health-science backbone for sport that reflect 5.1x–6.8x across category. Pair that with driven athlete partners, this fund turns that demand into deployable capital — in a category the market has structurally starved of investment. This further amped by the massive growth of the female athletic markets and our understanding of the underlying biology that fuels them.
Sports Focus: Training, Health Management, Recovery, Rehabilitation, Performance Longevity
Science Focus: Disease Prevention & Cure, Health Optimization above Baseline, Bionic Self, and Future of Longevity Innovations
FUND STRUCTURE
Generational Sports Science Fund I, LP — Backing the leading performance science companies for sports. A closed-end, 10-year vehicle focused across three vectors in sports science in early to mid stage innovative companies.
Carry: 80% LPs / 20% GP
General Partner: Angela Ruggiero & Sans Thakur with Athlete Partner and powered by TOWER the pioneer of Generational health
Anchor LP Minimum: $25M
Target Raise: $500M Maximum
Deployment: 1–3 year deployment window per asset, staged across the portfolio, disbursements concentrated in years 3-7.
Portfolio Mechanics:
25-30 investments in Series A and B companies
Check size between 5M - 25M per company, with discretion
Co-investment rights secured for priority LPs and family offices
The TRIO: athlete | SCIENTIST | INVESTOR
DEMAND, DESIGN & ELITE EXECUTION
Explosive, Investable Demand: Elite athletes are willing, motivated, biologically extreme test cases for performance science. Women's sport is growing more than 300% — and amplified by life sciences/tech-- the fastest-growing intersection. Where demand for longevity and biotech is no longer observable, it's investable.
Lean & Scalable by Design: A tiered athlete-engagement model — scales trust and access without diluting fund discipline. Athletes invest and vote or advise. Honoring athletes lived experience and ability to be owners and actors in the business.
Execution: Angela Ruggiero won Olympic gold, was inducted into the Hockey Hall of Fame, sat on the IOC's Executive Board, and formerly Chief Strategy Officer for the 2028 LA Olympics. Sans Thakur architected a $1.3 trillion scientific-asset model, executed in multiple unicorns, and has spent 25 years growing health-science and technology. Together, that's a combination of athlete credibility and capital discipline the market has never seen paired at this level.
GENERAL PARTNERS
ANGELA RUGGIERO
SANS THAKUR
Angela Ruggiero: Four-time Olympian and Olympic Gold Medalist. Named to Forbes's '25 Most Powerful Women in Sport.' CEO and Co-founder of Sports Innovation Lab with a successful exit, and acts a as global leader in fan data. Leads the Women's Sports Club. Eight years on the IOC and USOPC Executive Board. Former Chief Strategy Officer for the 2028 LA Olympics. Advisory Board, Boston Athletic Association. Executive Board, World Rugby. Executive Board, Golazo. 4th woman inducted into the Hockey Hall of Fame. Harvard MBA. Wharton PE certificate.
Sans Thakur: A global pioneer of Generational Health. Began her work to rethink Generational Science in 1997 on the human genome project.+25 years in health-science and technology. Ran one of the first CVC funds in digital health. Supported $9B in pharma strategy at Boehringer Ingelheim. Directed multi-billion-dollar portfolios. 100+ clinical trials. Lead Growth of double unicorn. Led Accenture's global life sciences practice across 24 markets. Author of New Science. Modeled $1.3T in scientific assets. Led the life-science COVID-19 response, assessing 50,000+ innovations. World Economic Forum Healthcare and Longevity Council leader. UN Population Fund strategic partner.
Angela brings operator grit with athlete trust, network, and lived understanding of elite performance. Sans brings innovator and capital discipline, scientific infrastructure, and a Generational Health record. — together they move at the speed of real athlete relationships while investing with rigor.
structural not symbolic
The commitment to athletes. OUR FIRST INVESTORS
The Voting Board | The Advisor Team | The Athlete Limited Partner:
Three ways for athletes to partner as operators, and investors to own and shape sports science companies and markets.
INVEST IN THE GREATEST OPPORTUNITY IN SPORTS TODAY: SPORTS SCIENCE
LED by Angela Ruggiero and Sans Thakur
built on TOWER Capital Group, the pioneer of Generational Health
Copyright 2026. Tower Capital Group LLC. All Rights Reserved
Important Disclosures and Disclaimers
This document is for informational purposes only and is intended exclusively for the use of the persons to whom it is delivered and the information provided therein is confidential and may not be reproduced in its entirety or in part, or redistributed to any party in any form, without the prior written consent of TOWER Capital Group, LLC, or any named affiliate entity (“TOWER” or “TOWER Capital”). Information contained in this document is current only as of the date specified in the document, regardless of the time of delivery or of any investment, and TOWER does not undertake any duty to update the information set forth herein.
Certain information included in this document is based upon information reasonably available to TOWER. Furthermore, the information included in this document has been obtained from sources TOWER believes to be reliable; however, these sources cannot be guaranteed as to their accuracy or completeness No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information contained in this document and no liability is accepted for the accuracy or completeness of any such information. TOWER maintains historical materials and disclosures in this document for archival and regulatory purposes. The information contained in such materials and disclosures is believed to be reliable at the time it is initially presented, and TOWER assumes no responsibility for updating information to reflect subsequent developments. Any transactions highlighted within investment updates in this material are not representative of the entire investment portfolio and there is no guarantee that other investments or transactions in the portfolio not described herein are/will be successful. For additional important disclosures and notices, please review our Notices page at www.towercapital.org/notices.